| 2.84 -0.05 (-1.73%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.41 | 1-year : | 3.99 |
| Resists | First : | 2.92 | Second : | 3.41 |
| Pivot price | 2.58  |
|||
| Supports | First : | 2.47 | Second : | 2.2 |
| MAs | MA(5) : | 2.79 |
MA(20) : | 2.53 |
| MA(100) : | 2.55 |
MA(250) : | 1.96 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 92.2 |
D(3) : | 91.4 |
| RSI | RSI(14): 64.4 |
|||
| 52-week | High : | 3.1 | Low : | 0.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OVID ] has closed below upper band by 18.8%. Bollinger Bands are 36.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.91 - 2.92 | 2.92 - 2.93 |
| Low: | 2.76 - 2.78 | 2.78 - 2.79 |
| Close: | 2.81 - 2.84 | 2.84 - 2.86 |
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Tue, 18 Aug 2026
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Fri, 14 Aug 2026
Ovid Therapeutics (OVID) investor reports 9.6M-share beneficial stake - stocktitan.net
Fri, 14 Aug 2026
RA Capital reports 9.99% Ovid Therapeutics stake (OVID) via stock and warrants - stocktitan.net
Fri, 14 Aug 2026
Ovid Therapeutics Inc (OVID) News, Articles, Events & Latest Updates - Stocktwits
Thu, 13 Aug 2026
Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Thu, 13 Aug 2026
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 187 (M) |
| Shares Float | 154 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 73.3 (%) |
| Shares Short | 22,040 (K) |
| Shares Short P.Month | 11,860 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.17 |
| Profit Margin | 0 % |
| Operating Margin | -678.7 % |
| Return on Assets (ttm) | -19.7 % |
| Return on Equity (ttm) | -18.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -13.53 |
| PEG Ratio | 0 |
| Price to Book value | 2.4 |
| Price to Sales | 74.44 |
| Price to Cash Flow | -12.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|